Pharma BD Deal Intelligence
Servier's $2B acquisition of Agios' oncology business was franchise-defining: gaining Tibsovo for IDH1-mutant cancers and vorasidenib for low-grade glioma. A rare case where a mid-market deal built an entire company's identity around a mutation-defined precision oncology portfolio.
Servier acquired Agios Pharmaceuticals' oncology business for up to $2B, gaining Tibsovo.
Servier completes acquisition of Agios Pharmaceuticals oncology business including TIBSOVO and vorasidenib for up to $2 billion.
Servier oncology revenue €2.21B in 2024/25 (+54.6%), driven by the U.S. launch of Voranigo; >5,500 patients on Voranigo globally; oncology now 32.2% of group…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Servier acquired Agios Pharmaceuticals' oncology business for up to $2B ($1.8B upfront plus a $200M milestone and a 5% royalty on future vorasidenib net sales), announced December 21, 2020 and completed April 1, 2021. The deal delivered Tibsovo (ivosidenib) for IDH1-mutant cancers plus the clinical-stage IDH pipeline led by vorasidenib. The thesis has since been realized: vorasidenib won FDA approval as Voranigo on August 6, 2024 — the first targeted therapy for Grade 2 IDH-mutant glioma (INDIGO phase 3, median PFS 27.7 vs 11.1 months) — and its U.S. launch drove Servier oncology revenue to €2.21B in 2024/25 (+54.6%), making the IDH franchise the anchor of Servier's precision-oncology identity.
20K US cases/yr · $2.8B US AML Market (2024)
Acute myeloid leukemia with IDH1 mutations represents a precision oncology target. Tibsovo (ivosidenib) is first-in-class, approved for relapsed/refractory and newly diagnosed AML unsuitable for intensive chemotherapy. The AGILE trial extended use to front-line combination with azacitidine.
Servier expanded the IDH franchise beyond AML into low-grade glioma with vorasidenib (Voranigo), creating a two-product franchise around IDH mutation testing. IDH mutation testing adoption is the critical commercial lever driving both products.
Servier completed up to $2B acquisition of Agios Pharmaceuticals' oncology business, gaining Tibsovo (ivosidenib) and the IDH mutation franchise.
FDA approved Voranigo for IDH-mutant grade 2 glioma, triggering $1.1B milestone to Agios. Second IDH franchise drug for Servier US.
Servier's IDH franchise (Tibsovo + Voranigo) expanding across AML, cholangiocarcinoma, and low-grade glioma with IDH testing as commercial lever.
Transformed Servier US into precision oncology company. Tibsovo established, Voranigo launched, IDH franchise anchors Servier's commercial identity.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Servier / Agios Pharmaceuticals (oncology) (this deal) | 2020 | $2.0B | 91 |
| Servier / Shire plc (Oncology Business) | 2018 | $2.4B | 88 |
| Servier / Edgewise Therapeutics, Inc. | 2026 | $2.6B | 75 |
| Servier / Symphogen A/S | 2006 | — | 66 |
| Servier / Aitia | 2024 | — | — |
| Servier / AmoyDx | 2024 | — | — |
| Servier / kyron.bio | 2026 | — | — |
← Browse all deals · How we score deals
More: 2020 deals · Servier deals · Oncology deals